The World Health Organization (WHO) recommended today not to use the ivermectina in patients suffering from covid-19. Its consumption is regardless of the severity of the symptoms they develop and their duration.
- How did the virus get to Wuhan?
The ivermectina is a low-cost drug against parasites that is used in many countries, especially of Latin America, in people infected with the coronavirus SARS-CoV-2. Despite the fact that its efficacy for this disease has not been validated by medical studies.
In Latin America The idea circulates that given in the first days after the onset of symptoms, it can prevent the disease from becoming serious. Supposed prophylactic effects are also attributed to it.
Only for clinical trials
The WHO affirms in a guide on therapies against covid-19, published today, that the ivermectina it should only be used in the context of clinical trials.
“The recommendation to use a drug only in the context of a clinical trial is appropriate when there is little evidence to offer certainty”, explains the Organization.
In his guide, he explains that little evidence has been drawn from trials that ivermectina have a beneficial effect. The results were obtained in terms of mortality, mechanical ventilation, hospital admission, length of hospitalization, and viral discharge.
The experts who looked at this question have determined that the fact that a drug is cheap and widely available does not justify its use if its benefit remains unclear.
Medicines authorized by the WHO
The only drugs that the WHO has deemed good for hospitalized patients with severe symptoms of COVID-19 are corticosteroids. In particular the dexamethasone, this is a low-priced product.
A week ago, the European Medicines Agency (EMA) He also advised against ivermectin to prevent and treat COVID-19. Warned that “The available data does not support” its widespread use outside of controlled clinical trials. EFE